Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1346-1363
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1346
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1346
Ref. | Trial | Clinical trials. gov, No. | Study design | Phase | Case, experimental vs control, (n) | Intervention methods | ORR (%) | DCR (%) | 12-mo OS (%) | 12-mo PFS (%) |
Bang | JAVELIN Gastric 300 | NCT02625623 | RCT | III | 371, 185 vs 186 | Avelumab 10 mg/kg Q2 W vs paclitaxel 80 mg/m2 or irinotecan 150 mg/m2 1, 8, 15 d of 4-wk cycles. | 2.2 | 22.2 | NA | NA |
Bang | KEYNOTE-059 (cohorts 2 and 3) | NCT02335411 | Single-arm | II | 31 | Pembrolizumab 200 mg on day 1 of 21-d cycles. | 25.8 | 35.5 | 63.0 | NA |
Boku | ATTRACTION-4 | NCT02746796 | RCT | II | 40, 21 vs 19 | Nivolumab 360 mg Q3 W + SOX or Cape OX. | 65.8 | 84.2 | NA | NA |
Chen | ATTRACTION-2 | NCT02267343 | RCT | III | 493, 330 vs 163 | Nivolumab 3 mg/kg Q2 W vs placebo 3 mg/kg Q2 W. | 11.9 | 40.3 | 87.1 | 9.3 |
Chung | JAVELIN Solid Tumor | NCT01772004 | Dose-escalation | I | 150 | Avelumab 10 mg/kg Q2 W. | 6.7 | 45.3 | 38.0 | 12.6 |
Doi T | JAVELIN Solid Tumor JPN trial | NCT01943461 | Single-arm | I | 40 | Avelumab 10 mg/kg Q2 W | 10.0 | 52.5 | 31.0 | NA |
Fuchs | KEYNOTE-059 (cohorts 1) | NCT02335411 | Single-arm | II | 259 | Pembrolizumab 200 mg Q3 W. | 11.6 | 27.0 | 23.4 | NA |
Herbst | JVDF | NCT02443324 | Single-arm | Ia/b | 41 | Pembrolizumab 200 mg on day 1 + ramucirumab 10 mg/kg days 1-8. | 7.3 | 51.2 | 30.8 | 12.3 |
Janjigian et al[36] 2018 | CheckMate-032 | NCT01928394 | Dose-escalation | I/II | 59 | Nivolumab 3 mg/kg Q2 W. | 12.0 | 32.0 | 39.0 | 8.0 |
Kelly | NA | NCT02340975 | RCT | Ib/II | 27 | Durvalumab 20 mg/kg + tremelimumab 1 mg/kg Q4W. | 7.4 | NA | 37.0 | NA |
Muro | KEYNOTE-012 | NCT01848834 | Single-arm | Ib | 39 | Pembrolizumab 10 mg/ kg Q2 W. | 22.0 | 33.0 | 42.0 | NA |
Shah | KEYNOTE-180 | NCT02559687 | Single-arm | II | 121 | Pembrolizumab 200 mg Q3 W. | 9.9 | 30.6 | 28.0 | NA |
Shitara | KEYNOTE-061 | NCT02370498 | RCT | III | 592, 296 vs 296 | Pembrolizumab 200 mg Q3 W vs paclitaxel 80 mg/m2 1, 8, 15 d of 4-wk cycles | 11.1 | 20.7 | 40.0 | NA |
- Citation: Yang L, Dong XZ, Xing XX, Cui XH, Li L, Zhang L. Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis. World J Gastrointest Oncol 2020; 12(11): 1346-1363
- URL: https://www.wjgnet.com/1948-5204/full/v12/i11/1346.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i11.1346